Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021,...